menu
    • menu
    [{"orgOrder":0,"company":"Perosphere Pharmaceuticals Inc","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Hematology","graph2":"Phase II","graph3":"Perosphere Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perosphere Pharmaceuticals Inc \/ Quintiles Inc","highestDevelopmentStatusID":"8","companyTruncated":"Perosphere Pharmaceuticals Inc \/ Quintiles Inc"},{"orgOrder":0,"company":"Perosphere Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Undisclosed","graph2":"Phase II","graph3":"Perosphere Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perosphere Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Perosphere Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Perosphere Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Undisclosed","graph2":"Phase II","graph3":"Perosphere Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perosphere Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Perosphere Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Perosphere Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Hematology","graph2":"Phase II","graph3":"Perosphere Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perosphere Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Perosphere Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Perosphere Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Undisclosed","graph2":"Phase II","graph3":"Perosphere Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perosphere Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Perosphere Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Perosphere Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ciraparantag","moa":"Dabigatran | Apixaban | Rivaroxaban | Heparin | Edoxaban","graph1":"Undisclosed","graph2":"Phase II","graph3":"Perosphere Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perosphere Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Perosphere Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Perosphere Pharmaceuticals Inc","sponsor":"Profil Institut f\u00fcr Stoffwechselforschung GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Perosphere Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perosphere Pharmaceuticals Inc \/ Profil Institut f\u00fcr Stoffwechselforschung GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Perosphere Pharmaceuticals Inc \/ Profil Institut f\u00fcr Stoffwechselforschung GmbH"},{"orgOrder":0,"company":"Perosphere Pharmaceuticals Inc","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compound","year":"2014","type":"Inapplicable","leadProduct":"14-C PER977","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Perosphere Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perosphere Pharmaceuticals Inc \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"6","companyTruncated":"Perosphere Pharmaceuticals Inc \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Perosphere Pharmaceuticals Inc","sponsor":"Duke Clinical Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Perosphere Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perosphere Pharmaceuticals Inc \/ Duke Clinical Research Institute","highestDevelopmentStatusID":"1","companyTruncated":"Perosphere Pharmaceuticals Inc \/ Duke Clinical Research Institute"}]

    Find Clinical Drug Pipeline Developments & Deals by Perosphere Pharmaceuticals Inc

    Menu

    Perosphere Pharmaceuticals Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Perosphere Pharmaceuticals Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Perosphere Pharmaceuticals Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ciraparantag

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT

                            Details : Ciraparantag is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 20, 2017

                            Lead Product(s) : Ciraparantag

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Perosphere Pharmaceuticals Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Perosphere Pharmaceuticals Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ciraparantag

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT

                            Details : Ciraparantag is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 01, 2017

                            Lead Product(s) : Ciraparantag

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Perosphere Pharmaceuticals Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Perosphere Pharmaceuticals Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ciraparantag

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Quintiles Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaba...

                            Details : PER977 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anticoagulation Reversal.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 04, 2014

                            Lead Product(s) : Ciraparantag

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Quintiles Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Perosphere Pharmaceuticals Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Perosphere Pharmaceuticals Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Duke Clinical Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Variability in the Measurement of WBCT Between Blood Drawn From Indwelling Catheters and Direct Venipuncture

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 04, 2014

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Duke Clinical Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Perosphere Pharmaceuticals Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Perosphere Pharmaceuticals Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ciraparantag

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Hepa...

                            Details : PER977 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 01, 2014

                            Lead Product(s) : Ciraparantag

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Perosphere Pharmaceuticals Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Perosphere Pharmaceuticals Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ciraparantag

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin

                            Details : PER977 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 01, 2014

                            Lead Product(s) : Ciraparantag

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Perosphere Pharmaceuticals Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Perosphere Pharmaceuticals Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Lispro

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Profil Institut für Stoffwechselforschung GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics of Ultra-Rapid-Acting Insulin Lispro (URAL) in Type 1 Diabetes Mellitus

                            Details : Insulin Lispro is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            August 01, 2014

                            Lead Product(s) : Insulin Lispro

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Profil Institut für Stoffwechselforschung GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Perosphere Pharmaceuticals Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Perosphere Pharmaceuticals Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 14-C PER977

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Worldwide Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Open-label, Single-dose, Non-randomized Study of IV 14C-labeled PER977 in Healthy Male Subjects

                            Details : 14-C PER977 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            August 01, 2014

                            Lead Product(s) : 14-C PER977

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Worldwide Clinical Trials

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Perosphere Pharmaceuticals Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Perosphere Pharmaceuticals Inc

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ciraparantag

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban

                            Details : PER977 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anticoagulation Reversal.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 08, 2013

                            Lead Product(s) : Ciraparantag

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth